CA3244229A1 - COMPOUNDS - Google Patents
COMPOUNDSInfo
- Publication number
- CA3244229A1 CA3244229A1 CA3244229A CA3244229A CA3244229A1 CA 3244229 A1 CA3244229 A1 CA 3244229A1 CA 3244229 A CA3244229 A CA 3244229A CA 3244229 A CA3244229 A CA 3244229A CA 3244229 A1 CA3244229 A1 CA 3244229A1
- Authority
- CA
- Canada
- Prior art keywords
- heterocycloalkyl
- alkyl
- cycloalkyl
- haloalkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021904274 | 2021-12-24 | ||
| AU2021904274A AU2021904274A0 (en) | 2021-12-24 | Compounds | |
| PCT/AU2022/051592 WO2023115166A1 (en) | 2021-12-24 | 2022-12-23 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3244229A1 true CA3244229A1 (en) | 2023-06-29 |
Family
ID=86900852
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3244229A Pending CA3244229A1 (en) | 2021-12-24 | 2022-12-23 | COMPOUNDS |
| CA3244224A Pending CA3244224A1 (en) | 2021-12-24 | 2022-12-23 | COMPOUNDS |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3244224A Pending CA3244224A1 (en) | 2021-12-24 | 2022-12-23 | COMPOUNDS |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20250074873A1 (enExample) |
| EP (2) | EP4452937A4 (enExample) |
| JP (2) | JP2025501630A (enExample) |
| CN (2) | CN118715204A (enExample) |
| CA (2) | CA3244229A1 (enExample) |
| WO (2) | WO2023115167A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| WO2022221415A2 (en) | 2021-04-13 | 2022-10-20 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
| EP4396162A4 (en) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| JP2025502615A (ja) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス，インク． | フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用 |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| CA3253725A1 (en) * | 2022-05-20 | 2023-11-23 | Caamtech, Inc. | TRYPTAMINE DERIVATIVES |
| AU2023323907A1 (en) * | 2022-08-11 | 2025-02-20 | Gilgamesh Pharmaceuticals, Inc. | Tryptamines and methods of treating mood disorders |
| CA3265884A1 (en) * | 2022-08-31 | 2024-03-07 | Cybin Irl Limited | TRYPTAMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| CN121866243A (zh) * | 2023-09-07 | 2026-04-14 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 致幻化合物、其制备方法及其用途 |
| WO2025137581A1 (en) * | 2023-12-21 | 2025-06-26 | Atai Therapeutics, Inc. | Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions |
| US12679847B1 (en) | 2025-08-04 | 2026-07-14 | Nalu Bio, Inc. | Aryl-substituted n-alkyl indoles and their use as pharmacologically active agents |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1928892A (en) * | 1991-06-21 | 1993-01-25 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists |
| GB9718833D0 (en) * | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
| AU767009B2 (en) * | 1998-12-11 | 2003-10-30 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| SI1379239T1 (sl) * | 2001-03-29 | 2008-02-29 | Lilly Co Eli | N-(2-ariletil)benzilamini, uporabljeni kot antagonisti receptorja 5-ht6 |
| KR20050010512A (ko) * | 2002-06-12 | 2005-01-27 | 스미또모 세이야꾸 가부시키가이샤 | 인돌, 인다졸 및 벤즈아졸류 |
| CA2508290C (en) * | 2002-12-20 | 2017-02-28 | Ciba Specialty Chemicals Holding Inc. | Synthesis of amines and intermediates for the synthesis thereof |
| ES2564804T3 (es) * | 2004-02-12 | 2016-03-29 | Mitsubishi Tanabe Pharma Corporation | Compuesto de indazol y uso farmacéutico del mismo |
| WO2006047032A2 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| WO2007046112A1 (en) * | 2005-10-19 | 2007-04-26 | Suven Life Sciences Inc. | Arylthioether tryptamine derivatives as functional 5-ht6 ligands |
| WO2008046155A1 (en) * | 2006-10-20 | 2008-04-24 | Dia-B Tech Limited | Methods for regulating glucose homeostasis and agents therefor |
| US20090318527A1 (en) * | 2008-02-11 | 2009-12-24 | Howard Sard | Indole compounds and methods of use thereof |
| BRPI0916395A2 (pt) * | 2008-07-30 | 2016-02-16 | Ferrer Int | compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno |
| US8349898B2 (en) * | 2008-11-18 | 2013-01-08 | Wisconsin Alumni Research Foundation | Sigma-1 receptor ligands and methods of use |
| US8912220B2 (en) * | 2009-08-10 | 2014-12-16 | Galenea Pharmaceuticals | Compounds and methods of use thereof |
| CN103601683B (zh) * | 2010-04-16 | 2016-03-30 | 中国科学院上海药物研究所 | 苯并杂环类化合物及其制备方法和用途 |
| USRE47009E1 (en) * | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| WO2021179091A1 (en) * | 2020-03-12 | 2021-09-16 | Bright Minds Biosciences Inc. | 3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators |
| IL312785B2 (en) * | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US20230014907A1 (en) * | 2020-06-12 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| WO2022246554A1 (en) * | 2021-05-26 | 2022-12-01 | Bright Minds Biosciences Inc. | Heterocyclic compounds and methods of preparation thereof |
-
2022
- 2022-12-23 CA CA3244229A patent/CA3244229A1/en active Pending
- 2022-12-23 US US18/723,836 patent/US20250074873A1/en active Pending
- 2022-12-23 EP EP22908928.9A patent/EP4452937A4/en active Pending
- 2022-12-23 JP JP2024538682A patent/JP2025501630A/ja active Pending
- 2022-12-23 CN CN202280091813.9A patent/CN118715204A/zh active Pending
- 2022-12-23 US US18/723,719 patent/US20250101038A1/en active Pending
- 2022-12-23 EP EP22908929.7A patent/EP4452938A4/en active Pending
- 2022-12-23 CN CN202280091811.XA patent/CN118696029A/zh active Pending
- 2022-12-23 WO PCT/AU2022/051593 patent/WO2023115167A1/en not_active Ceased
- 2022-12-23 WO PCT/AU2022/051592 patent/WO2023115166A1/en not_active Ceased
- 2022-12-23 JP JP2024538674A patent/JP2025501629A/ja active Pending
- 2022-12-23 CA CA3244224A patent/CA3244224A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118715204A (zh) | 2024-09-27 |
| EP4452937A4 (en) | 2025-12-03 |
| WO2023115167A1 (en) | 2023-06-29 |
| WO2023115166A1 (en) | 2023-06-29 |
| US20250074873A1 (en) | 2025-03-06 |
| EP4452938A4 (en) | 2025-12-03 |
| CN118696029A (zh) | 2024-09-24 |
| JP2025501630A (ja) | 2025-01-22 |
| JP2025501629A (ja) | 2025-01-22 |
| US20250101038A1 (en) | 2025-03-27 |
| CA3244224A1 (en) | 2023-06-29 |
| EP4452937A1 (en) | 2024-10-30 |
| EP4452938A1 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250101038A1 (en) | Compounds | |
| US20250163044A1 (en) | Compounds | |
| CN104725359B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| CA2715282A1 (en) | Indole compounds and methods of use thereof | |
| US12415804B2 (en) | Compounds for activating a serotonin receptor | |
| JP2018076365A (ja) | 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体 | |
| US20250333371A1 (en) | Compounds | |
| US12428380B2 (en) | Compounds | |
| WO2025118034A1 (en) | Compounds active at the serotonergic 5-ht2a receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241205 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241205 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241205 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250127 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250214 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250304 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250311 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251223 |